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Atrial fibrillation (AF) is the commonest cardiac rhythm disorder. Evaluation of patients with AF requires an electrocardiogram, but imaging
techniques should be considered for defining management and driving treatment. The present document is an expert consensus from the Euro-
pean Association of Cardiovascular Imaging (EACVI) and the European Heart Rhythm Association. The clinical value of echocardiography, car-
diac magnetic resonance (CMR), computed tomography (CT), and nuclear imaging in AF patients are challenged. Left atrial (LA) volume and
strain in echocardiography as well as assessment of LA fibrosis in CMR are discussed. The value of CT, especially in planning interventions, is
highlighted. Fourteen consensus statements have been reached. These may serve as a guide for both imagers and electrophysiologists for best
selecting the imaging technique and for best interpreting its results in AF patients.
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Introduction
Evaluation of patients with atrial fibrillation (AF) requires an as-
sessment of cardiac structure and function. Such an assessment
complements the clinical evaluation, and helps decision-making
regarding rhythm strategy (rhythm control vs. rate control), stroke
risk stratification, and prognosis. Increasingly sophisticated im-
aging techniques are now available and have been used for this
purpose.
To address the role of multi-modality imaging for the evaluation
of patients with AF, a Task Force was convened by the European
Association of Cardiovascular Imaging (EACVI) and the European
Heart Rhythm Association (EHRA), with the remit to comprehen-
sively review the published evidence available, to publish a joint ex-
pert consensus document on the role of imaging techniques and
their applications in patients with AF, and to provide recommenda-
tions for their use in clinical practice.
A. Epidemiology, pathophysiology,
and clinical background
AF is the commonest sustained cardiac arrhythmia and represents a
global healthcare problem, with an increasing prevalence and inci-
dence.1 People over the age of 40 have a one in four lifetime risk
of developing AF, which is more common in association with in-
creased age, medical comorbidities [e.g. systemic arterial hyperten-
sion, heart failure (HF), prior myocardial infarction, sleep apnoea,
obesity, alcohol excess, etc.].2 Some of the risk factors for AF also
contribute to its complications, particularly stroke and thrombo-
embolism and HF.
Most commonly, patients have so-called non-valvular AF,
which is defined as AF in the absence of prosthetic mechanical
heart valves, or ‘haemodynamically significant valve disease’.3,4
The 2012 focused update of the ESC guidelines states that it is
conventional to divide AF into cases that are described as ‘valvu-
lar’ or ‘non-valvular’.5 Valvular AF was defined as rheumatic
valvular disease (predominantly mitral stenosis) or prosthetic
heart valves. Similarly, the 2014 AHA/ACC/HRS Guideline for
the management of patients with AF defined non-valvular AF as
AF in the absence of rheumatic mitral stenosis, or a mechanical
heart valve, but explicitly added bio-prosthetic heart valves or
mitral valve (MV) repair.6 Of note, significant valve disease was
generally excluded from the recent randomized trials of stroke
prevention in AF. In the RE-LY trial, patients with ‘severe heart
valve disorder’ were excluded, whereas the ROCKET-AF trial
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excluded those with ‘haemodynamically significant MV stenosis’
and the ARISTOTLE trial excluded those with ‘moderate or se-
vere mitral stenosis’.7 – 10
Cardiovascular imaging can provide insights into the aetiology,
pathophysiology, risk stratification, and some therapeutic interven-
tions in patients with AF. Management decisions on rate and/or
rhythm control are determined by patient symptoms and ECG
phenotypes.
Nonetheless, AF is a chronically progressive disease. In the ESC
guidelines, the five clinical subtypes of AF encompass the progression
from undiagnosed episodes through first diagnosis and infrequent
paroxysms to long-lasting persistent and eventually permanent AF11
(Box 1).
While AF increases the risk of stroke and thromboembolism
five-fold, this risk is not homogeneous, and depends on the pres-
ence of various stroke risk factors.12 The major guidelines (Euro-
pean,13 American,14 NICE15) all now recommend the use of a
clinical risk factor-based approach, with the CHA2DS2-VASc
score.16
The ‘C’ criterion in the CHA2DS2-VASc score refers to:
– Recent congestive HF whether with reduced or preserved ejec-
tion fraction (EF) (thus, including patients with moderate–severe
systolic impairment, cardiomyopathy, etc.).
– LV systolic dysfunction defined by LVEF ≤ 40%.
Left atrial (LA) dilatation is often associated with AF. It is associated
comorbidities. It has not been demonstrated as an independent
prognostic marker of stroke in multivariable analysis.17,18
Additional refinement of stroke risk stratification is obtained by
imaging, for example, using transoesphageal echocardiography
(TOE) where spontaneous echo-contrast, reduced LA appendage
(LAA) velocities, or complex aortic plaque all increase the potential
for stroke risk.19 Given that most thrombi form within LAA, cardiac
imaging plays a role when LAA occlusion is being considered as an
interventional procedure.
B.Overview of anatomy of the atria
and of the pulmonary veins
Normal LA structure and function
The LA modulates LV filling through three components: reservoir
phase of expansion during systole, a conduit phase during early dia-
stole, and an active contractile component during late diastole.20
Augmented LA booster pump function is one of the mechanisms
compensating for decreased early filling in patients with reduced
LV compliance, whereas a loss of atrial contraction reduces cardiac
output by 15–20%.21,22 An increase in LA contractility is consid-
ered to be caused by the increase of LA volume (Frank–Starling’s
law) (Figure 1). As a result of optimal use of the Frank–Starling
mechanism of the atrial muscle, atrial shortening is remarkably aug-
mented with chamber dilation. When the extent of LA shortening
and expansion is diminished, despite the geometrical advantage of
a further increase in atrial diameter, extreme dilation no longer
provokes the Frank–Starling response and the atrial myocardium
is made to operate on a ‘descending limb’ of function.23 The body
forms the central part of LA with LAA bulging superiorly and
leftward as a tube-like structure to pass round the origin of the
pulmonary trunk.24
Surrounding the mitral orifice is the vestibular component. The
pectinate muscles are confined within the appendages. The muscles
build a complicated network of muscular ridges lining the endocar-
dial surface.24 The LA is smooth walled on its internal aspect. In gen-
eral, LA walls are thicker than right atrial walls.25 The thickness of LA
muscle ranges from 3.5 to 6.5 mm.26 The LA wall thickness ranges
from 2.5 to 4.9 mm. The LA anterior wall ranges from 1.5 to
4.8 mm.24 Interestingly, there is an area of the anterior wall just
behind the aorta that is exceptionally thin, an area noted by
McAlpine as the ‘unprotected’ area at risk of perforation. The pos-
terior LA wall, closely related to the oesophagus, has a thickness of
4.1+ 0.7 mm.
The posterior part of LA is the venous component.24 During
heart development, the oblique vein of LA (vein of Marshall) passes
from a superior aspect onto the epicardial surface of LA in between
LAA and the left superior pulmonary vein to descend along the pos-
terolateral LA wall to join the coronary sinus. In the minority of pa-
tients, the lumen of the oblique vein remains patent.25 In the
majority, however, the vein is obliterated and forms the ligament
of Marshall. Within LA itself, there is a much more irregular arrange-
ment of the myocytes, the alignment often changing at different
depths within LA walls. In general, myocytes are aligned parallel to
the atrioventricular grooves in the vestibule, but transversely across
the atrial roof.22
Pulmonary veins
In general, four pulmonary veins enter the LA (common ostia, acces-
sory pulmonary veins are some of the possible anatomic variants that
can be found especially by cardiac CT) (Figure 2). However, the anat-
omy is variable with common ostia from superior and inferior veins or
additional veins. The histology is complex and described elsewhere.
Box 1 Clinical subtypes of AF in the ESC guidelines
on AF.11
1. Every patient who presents with AF for the first time is con-
sidered a patient with first diagnosed AF, irrespective of the
duration of the arrhythmia, or the presence and severity of
AF-related symptoms.
2. Paroxysmal AF is self-terminating, usually within 48 h.
Although AF paroxysms may continue for up to 7 days,
the 48 h time point is clinically important. After this period,
anticoagulation must be considered and the likelihood of
spontaneous conversion decreases.
3. Persistent AF is present when an AF episode either lasts
longer than 7 days or requires termination by cardioversion,
either with drugs or by direct current cardioversion (DCC).
4. Long-standing persistent AF has lasted for more than 1 year.
5. Permanent AF is said to exist when the presence of the ar-
rhythmia is accepted by the patient and physician. Hence,
rhythm control interventions are, by definition, not pursued
in patients with permanent AF.
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Figure 2 Example of the LAA cavity and the corresponding emptying flows. (A) Normal left appendage with normal emptying flows; (B) com-
plex morphology of the left appendage with a large thrombus coming from the bottom to the mouth of the cavity and the corresponding severely
blunted flows recorded with the pulse Doppler at the level of the appendage mouth.
Figure 1 Presentation of the pathophysiology of LA (AL) remodelling and the relationship between each kind of remodelling.
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Of note, at the veno-atrial junctions, there are abundant autonomic
nerve bundles, ganglia, and nerve plexuses situated in the epicardial
fat pads.27,28 The mitral isthmus extends between the orifice of the
left inferior pulmonary vein and the mitral hinge line. An imaging
analysis of 169 patients with cardiac CT showed a significant, dir-
ect, relationship between AF burden and the thickness of the pos-
terior peri-atrial fat pad between the oesophagus and the left
atrium.29
LA appendage
The LAA can be considered as a remnant of the embryonic LA.30,31
The anatomy and volume of LAA is highly variable with estimated
surface areas of 3.0–6.0 cm2.30 Dilatation of the atria appears to
be induced, to some extent, by increased expression of protease
(ADAM), which causes loss of cell–cell and cell–matrix interac-
tions.32 In physiology, LAA appears to contribute to the regulation
of cardiovascular pressure–volume relations since it is the main
source of synthesis of atrial natriuretic peptides.20,33 Amputation
of both appendages may induce significant alterations in fluid
haemostasis and oedema formation.
LAA is the most prominent site for LA thrombus formation, es-
pecially in patients with AF.22 Loss of regular atrial contractions re-
duces blood flow velocities, particularly in the atrial appendages, and
activates the clotting system (Figure 3).
C. Non-valvular AF: how to assess
the atria and the heart functions
1. Standard echocardiography
1.1 LA size and function
Among patients with AF, LA enlargement has been suggested as a
predictor of stroke in several studies.34 Most of the investigations re-
garding the prognostic impact of LA size relied on the antero-
posterior diameter measured by M-mode (AP diameter). However,
this method is based in several geometric assumptions that often re-
sult in LA size under-estimation.35 LA enlargement is often asym-
metrical, as enlargement in AP axis may be limited by the thoracic
cavity, and it may also occur in medial– lateral or superior–inferior
axes.36 In 317 patients in normal sinus rhythm, LAVi measured from
biplane 2D-apical views was superior to four-chamber LA area and
M-mode LA dimension in predicting the development of first AF,
congestive heart failure (CHF), stroke, transient ischaemic attack,
acute myocardial infarction, coronary revascularization, and cardio-
vascular death over 3.5 years of follow-up.37 Unfortunately, the
maximal LA volume that one might tolerate to predict the success
of an intervention remains unknown. From AFFIRM, the need for
more than two cardioversions in the first year in patients taking anti-
arrhythmic medication included left atrial diameter .4.5 cm.
Nevertheless, sensitivity and specificity of this was low.38
Figure 3 Analysis of the LA appendage. (I) 3D and corresponding 2D images; (II) pulse Doppler). (III) Navigation in the LAA volume for dis-
tinguishing a pectinae muscle from a thrombus. (IV) Corresponding ‘ideal’ 2D image showing a small thrombus within trabeculations.
EACVI/EHRA Expert Consensus Document 359
Downloaded from https://academic.oup.com/ehjcimaging/article-abstract/17/4/355/2464865
by Belgrade University user
on 13 March 2018
Of note, mitral annular calcification has been shown to be an in-
dependent predictor of the occurrence of AF. Also mitral annular
calcifications have been shown to be an independent predictor of
adverse outcomes such stroke and death,39,40 and has been asso-
ciated with aortic atheroma.41
Thus, LA AP diameter has been considered inaccurate, while
LA areas or volumes assessed by TTE rely on fewer geometric as-
sumptions.42 However, a complete assessment of the LA size and
function may not rely on maximum LA volume alone, as LA dimen-
sions vary widely during the cardiac cycle. An electrocardiogram-
guided echocardiography allows an accurate quantification of LA
functions by measuring LA volumes at different times during the car-
diac cycle: at end-systole, the LA maximum volume, at end-diastole,
minimum LA volume, at mid-diastole, just before atrial contraction,
pre-A-volume.43 The combination of these LA volumetric measure-
ments allows the calculation of the indices corresponding to the
three basic functions of the LA, reservoir function, conduit function,
and booster pump function.23
Functional assessment of the LA also includes the evaluation of
the pulmonary vein and transmitral flow, also used to describe
LV diastolic function, which was shown to greatly influence
LA size and function. One previous study44 demonstrated that
reduced LA reservoir function increases the risk of new-onset
AF independently of LA volume. More recently, Hirose et al.45
showed that LA booster pump function was a much better pre-
dictor of new-onset AF than LA dimension or LA volume
(Figure 4).
LA structural remodelling is often accompanied by a change in LA
function with a progressive increase in interstitial fibrosis.46,47 The
reduction in LA booster pump function may be a manifestation of
LA mechanical remodelling leading to the development of
new-onset AF, up to the loss of booster function in patients with
permanent AF.
Key point 1
Measuring LA biplane volume, using either the area–length or the
discs formula indexed by body surface area (BSA), is the method
currently recommended for LA size quantification. A normal LA
volume is defined as ,34 mL/m2.
1.2 LA/LAA thrombi and their predictors
Thromboembolism is the most dangerous complication of AF. Echo-
cardiography is a widely used technique that allows gathering a variety
of information about thrombo-embolic risk in patients with AF.48
The complementary role of echocardiographic measurements to
better refine the predictive value of clinical risk scores such as
CHADS2 and CHA2DS2-VASc is well recognized.
49 – 51 LA size
and independently LVEF are predicting the risk of thrombo-embolic
events in SPAF. e′ and s′ have been demonstrated as well as LA
strain, LAA spontaneous echo-contrast is other study summarized
recently, by Szymanski et al.51
TOE allows the following information to be obtained in a patient
with AF:
– A 2D multiplane or 3D analysis of the complexity of LAA anatomy.
– A semi-quantitative classification of the degree of spontaneous
echo-contrast.
– A Doppler measurement of the LAA emptying flows.
Spontaneous echocardiographic contrast (SEC), also known as
‘smoke’ or ‘swirl’, can be considered as the initial stage of thrombus
formation52 and is associated with low flow states53(Table 1). More-
over, increasing severity of SEC is associated with decreased LAA
flow velocity and increased LA size.54,55 Sludge is a dense SEC,
with a viscid, but not solid echodensity. It is often difficult to
Figure 4 Parameters for estimation of right atrial filling pressures.
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differentiate from a thrombus that represents a stage beyond SEC
along the continuum towards thrombus formation and appears to
have greater prognostic significance than smoke56–58 (Figure 3).
LAA thrombus and dense SEC are independent predictors of car-
diovascular death, even if compared with other clinical risk factors,
such as congestive HF, diabetes mellitus, systemic arterial hyperten-
sion, and vascular disease.59,60
Transthoracic echocardiography (TTE) parameters are useful
tools for the refinement of clinical risk scores.61
TTE-derived measurements can allow the prediction of pro-
thrombotic changes in the LA and LA appendage but cannot avoid
TOE in most individuals.
In the Stroke Prevention in AF study, systolic dysfunction was
identified as an independent predictor of ischaemic stroke and
systemic embolism.17,18 In the AF Investigators analysis, the pres-
ence of moderate– severe LV dysfunction on 2D echocardiog-
raphy was the only independent predictor of stroke.62 LA
dilatation or LV hypertrophy was only predictive of stroke on uni-
variable analysis but did not emerge as an independent predictor
on multivariable analysis.
Thus, an LVEF,40% is considered to be the equivalent of the con-
gestive HF criterion in the CHA2DS2-VASc score.
16 A normal LV EF
has been associated with the weak prevalence of LAA thrombus in
patients with AF undergoing TOE.63 Moreover, assessment of the
LVEF has increased the discriminative capability of clinical classifica-
tions (CHADS2 and CHA2DS2-VASc scores):
64 LVEF, indexed LAvol-
ume, and CHADS2 score were independent predictors of LAA
thrombus formation, and their combination was a useful measure
for identifying patients at low risk for LAA thrombus formation.64
In a study about 295 patients with non-valvular AF and CHADS2
scores of 0 or 1. All patients underwent TOE before cardioversion
and authors reached to the conclusion that: an LVEF , 40% and an
LA antero-posterior diameter.50 mm are independent predictors
of the presence of SEC and thrombus.65 This measurement of LA
diameter has been used for many years and has been demonstrated
to be related to the prognosis. Nevertheless, current practice
should be based on the LA-indexed volume. Epidemiological evi-
dences of the value of LA volume are existing and will confirm
that LA diameter should be replaced.37
In addition, LV diastolic function has a relationship with thrombo-
embolic risk in patients with AF: the E/e′ ratio was independently
associated with ischaemic stroke on multivariable analysis in a cross-
sectional study including 330 patients with persistent AF and
preserved LVEF.66 Peak annular systolic (s′) and early diastolic (e′)
velocities, particularly when combined, have been shown to be inde-
pendent predictors of a composite of cardiovascular death, recur-
rent HF, and ischaemic stroke in a cohort study of 148 patients
with AF and HF with preserved LVEF with a median follow-up of
27 months.67
Key point 2
An echocardiographic examination is recommended for every pa-
tient with AF to assess cardiac structure and function. An estimate
of the degree of atrial remodelling is important (value of indexed
LA volume). In addition, transthoracic echocardiography can help
to assess the risk of LAA thrombus and help to select patients with
an indication to TOE.
Past studies have used the theoretically simple measurement
of LA diameter using the para-sternal long-axis M-mode ap-
proach. Nowadays, LA-indexed volumes should be preferred.
Key point 3
TOE is the most reliable test to rule-out the presence of an LAA
thrombus before cardioversion of AF in non-anticoagulated pa-
tients and in patients with past diagnosis of LAA thrombus or
stroke/TIAs.
1.3 Guiding cardioversion
Pre-cardioversion: assessment of associated cardiac diseases and
outcome of cardioversion.
Echocardiographic screening is part of the evaluation of
every patient with AF.68,69 First, before cardioversion a TTE is in-
dicated to decide whether or not to proceed with a cardioversion
strategy.5,70 Clinical markers of failure of a rhythm control
strategy have been identified, e.g. summarized in the HATCH
score (which stands for hypertension, age.75 years, thrombo-
embolic event, pulmonary disease and HF.71 Also, echocardiog-
raphy is providing essential information. Atrial sizes (indexed LA
volume), LV systolic and diastolic functions, severity of valvular dis-
eases, and presence of LV hypertrophy all affect the outcome of
rhythm control.
Therefore, echocardiography is needed to assess the likelihood of
successful rhythm control.72
Key point 4
The absence of randomized study or large registry demonstrating
the prognostic value of imaging techniques in AF patients is never-
theless a real weakness for echocardiography and other imaging
techniques.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Classification of the spontaneous
echo-contrast according to corresponding emptying
flow velocities54,55
2D Echocardiographic
description
Emptying
flow
velocities
Sludge Dense smoke, viscid
echodensity, not solid
,20 cm/s
Severe
spontaneous
echo-contrast
Intense echodensity and very
slow swirling patterns in
the left acid appendage,
20–40 cm/s
Mild to moderate
spontaneous
echo contrast
Swirling pattern in the LA
appendage
40–60 cm/s
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Pre-cardioversion: assessment of stroke risk in not anticoagulated
or inadequately anticoagulated patients.
TOE-guided cardioversion is an alternative to anticoagulation
prior to cardioversion if AF lasts .48 h in patients who were
not anticoagulated or were inadequately anticoagulated during
the last 3 weeks prior to cardioversion.73 The presence of a
thrombus in the LAA is a contraindication to the performance of
cardioversion because of the associated risk for stroke. Therefore,
when a rhythm control strategy is chosen in not anticoagulated
or inadequately coagulated patients with AF . 48 h or if the dur-
ation is unknown, TOE is recommended to exclude LAA thrombus
as an alternative to 3 weeks of effective pre-cardioversion
anticoagulation.
Per and post-cardioversion: echocardiography can be used for
monitoring the heart recovery (LA, LAA but also LV stunning).74
The difficulty is that the duration of that stunning is variable and
has not been extensively studied during the 3 weeks following a car-
dioversion despite the recommended duration of the anticoagula-
tion of 3 weeks after the cardioversion that one is classically
considering.75
1.4 Echocardiography and LV systolic function
AF is frequently associated with LV systolic dysfunction or its ex-
acerbation by worsening haemodynamics, sympathetic activation,76
and by tachycardia-induced cardiomyopathy.77 Tachycardia-
induced cardiomyopathy is a condition in which atrial or ventricular
tachyarrhythmias or frequent ventricular ectopy result in left ven-
tricular (LV) dysfunction, leading to systolic HF. The hallmark of
this condition is partial or complete reversibility once arrhythmia
control is achieved. Tachycardia-induced cardiomyopathy can be
classified into two categories: one in which arrhythmia is the sole
reason for ventricular dysfunction (arrhythmia induced) and an-
other in which the arrhythmia exacerbates ventricular dysfunction
and/or worsens HF in a patient with concomitant heart disease
(arrhythmia mediated).78
Tachycardia-induced cardiomyopathy is a distinct entity that could
be characterized by:
– LV systolic dysfunction that is completely or at least partially
reversible after the correction of the arrhythmia or the control
of the rhythm.
– LV dysfunction without any severe LV enlargement79 and no
specific aetiology except the rhythm disorder.
– The related to the arrhythmia LV systolic dysfunction is hardly
predictable.
Key point 5
In AF, the LV systolic dysfunction might be totally or at least par-
tially related to some degree of tachycardia-induced cardiomyop-
athy. Usually in tachycardia-induced cardiomyopathy, the LV is
weakly or not enlarged.
In the opposite, LV systolic dysfunction is associated with an in-
creased risk of AF.62 This association is at high risk of stroke.80
While most information is available from HF patients with re-
duced LV function, stroke risk may also be increased in patients
with newly diagnosed HF and in those suffering from HF and pre-
served EF.81,82
LVEF is still the most used parameter of LV-systolic function and
in clinical practice. It has an important prognostic value in all cardiac
disorders, including AF.83
The LVEF affects the pharmacological agents that could be cho-
sen. No flecainide if LVEF is decreased, but instead, amiodarone
or digoxin could be discussed.
However, echocardiographic assessment of LV longitudinal
function may overcome many limitations of LVEF and provide add-
itional and/or incremental prognostic information. Mitral annular
plane systolic excursion using guided 2D M-mode imaging is a dir-
ect, early, and sensitive index of LV systolic dysfunction, even in
the presence of preserved LVEF in several cardiac pathologies, in-
cluding arterial systemic hypertension.84 The measurement of s′ at
the junction between basal myocardium and mitral annulus by
pulsed tissue Doppler is another parameter of LV longitudinal
function at LV base, an early marker of subtle LV systolic dysfunc-
tion, simple to measure and with good reproducibility and feasibil-
ity. When available, global longitudinal strain (GLS) by speckle
tracking echocardiography is the optimal parameter to quantify
accurately LV longitudinal function, even in AF patients.85 One
beat 3D or tri-plan acquisition can be performed in AF patients.
For the prediction of the risk of cardio-vascular events, a cut-off
of 212.5% has been proposed.86
Atrial cardiomyopathy, atrial Fibrillation, and thromboembolism
Recently, Hirsh et al.87 highlighted the concept of atrial cardiomyop-
athy, proposed previously, and characterized by an unusual exten-
sive fibrosis of the LA. As discussed in the present paper,
advances in non-invasive cardiac imaging allow the detection, local-
ization of atrial fibrosis as well as its consequences on the LA func-
tions. Inflammation, genetic factors might explain why some patients
do develop this cardiomyopathy and some other don’t. That inter-
patient variability might have to be assessed for a best individual
prediction of the thombo-embolic risk.
1.5 LV diastolic function and estimate of LV filling
pressures
LV diastolic dysfunction is an independent predictor of AF in the
elderly.88 Approximately 25–35% of patients with new onset of
diastolic HF have evidence of AF89 and the prevalence increases
with the severity of HF, reaching up to 40% in advanced stages.90
In HFpEF, up to 70% of the population has a history of AF.91
In the echocardiographic evaluation of diastolic dysfunction in
AF, atrial contraction is lost; consequently, there is no transmitral
A (mitral end-diastolic inflow) velocity and no pulmonary Ar (pul-
monary vein reversal flow) velocity. Therefore, transmitral E/A ra-
tio and the difference in Ar-A time duration cannot be used.
Nonetheless, other diastolic parameters independent of atrial in-
fluence could be measured such as E-velocity deceleration time
(DT) on transmitral E wave, isovolumetric relaxation time
(IVRT), systolic velocity (S) on pulmonary venous flow, e′ velocity
on pulsed tissue Doppler, E/e′ ratio.92 The E/e′ ratio has been
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demonstrated to be an accurate estimate of LV filling pressures in
patients with AF93 (Table 2).
The Doppler estimation of LV-filling pressures in AF is limited by
the variability in cycle length, the absence of organized atrial activity,
and the frequent occurrence of LA enlargement. In general, when
LVEF is depressed, mitral DT (≤150 ms) has a reasonable accuracy
for the prediction of increased filling pressures. Other Doppler
measurements that can be applied include: the peak acceleration
rate of mitral E velocity (≥1900 cm/s2), IVRT (≤65 ms), DT of pul-
monary venous diastolic velocity [≤220 ms, eventually the E/Vp ra-
tio (≥1.4)], and the E/e′ ratio (≥11) that predicts LVEDP ≥
15 mmHg. The variability of mitral inflow velocity with the RR cycle
length should be taken into account, because patients with in-
creased filling pressures have less beat-to-beat variation. The aver-
age of measurements from 10 cardiac cycles is most accurate,
though velocities and time intervals averaged from three non-
consecutive beats with cycle lengths within 10–20% of the average
heart rate and measurements from one cardiac cycle with an RR
interval corresponding to a heart rate of 70–80 b.p.m. are still
useful.93,94
Key point 6
In AF, the comprehensive assessment of LV diastolic function and
filling pressures required a combination of several parameters.
Mitral annular early diastolic velocity by pulsed tissue Doppler
is a marker of LV diastolic dysfunction, and septal e ′ ,8 cm/s
has a reasonable accuracy to identify LV delayed relaxation.
1.6 RA size and function
The right atrium (RA) assists in filling the right ventricle (RV) by act-
ing as a reservoir for systemic venous return when the tricuspid
valve is closed, acting as a passive conduit in early diastole when
the tricuspid valve is open and acting as an active conduit in late dia-
stole during atrial contraction.
Relationship between enlargement and remodelling of both atria
and AF has been described.99 The RA area is even a prognostic index
of maintenance of sinus rhythm after AF ablation and its reverse re-
modelling has been described, for instance, after radiofrequency ab-
lation treatment of AF.100
Two-dimensional echocardiographic assessment of RA diameter
has been performed by measuring the following:101 (i) RA area (traced
at the end of ventricular systole (largest volume), normal value
,18 cm2); (ii) RA length (maximal long-axis distance from the centre
of the tricuspid annulus to the centre of the superior RA wall, parallel
to the interatrial septum, normal value ,53 mm); and (iii) RA diam-
eter (mid-RA minor distance, defined from the mid-level of the RA
free wall to the interatrial septum, perpendicular to the long axis, nor-
mal value,44 mm). RA volume has to be now the main measure that
is advised by the 2015 ASE/EACVI recommendations42 (Figure 5).
Key point 7
The normal range for 2DE RA volume index is 25+7 mL/m2 in men
and 21+6 mL/m2 in women.42 RA volume. 30 mL/m2 represents
for sure a pathological enlargement of the RA.
RA pressure is most commonly estimated by inferior vena cava
diameter and the presence of inspiratory collapse. In cases where
these parameters are not discerning, complementary indices are con-
sidered such as hepatic vein flow pattern and the diastolic filling pat-
tern of the RV measured through Doppler imaging (Figure 6).
Normally, using Doppler, the hepatic vein systolic filling fraction,
which is the ratio of the velocity–time integrals (VTIs) (VTIsystole/
[VTIsystole + VTIdiastole]), can be obtained. A value ,55% was found
to be the most sensitive (86%) and specific (90%) sign of RA pressure
.8 mmHg. With higher RA pressure, there was a decrease in systolic
filling fraction. The presence of atrial fibrillation causes the hepatic
vein systolic flow to be diminished regardless of RA pressure.102
TEE: it has recently been discussed the relevance of analyses of
the right atrial appendage and not only the LAA in patients present-
ing an atrial arrhythmia. Among 983 patients with complete anatom-
ic studies of the LAA and RAA, the incidence of LAA thrombus was
9.3% (91 of 983) and 0.73% (7 of 983) in the RAA (P , 0.01).103
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Table 2 Parameters which can be used to evaluate LV filling pressure in patients with AF
Parameter Cut-off values for increased
LV filling pressure
References Comment
Mitral flow EDT ,150 ms Matsukida, 200195
Nagueh, 199693
Temporelli, 199996
Chirillo, 199797
Correlation with LVFP is stronger when LVEF is reduced
and it should not be used when LVEF is normal.
EDT should be measured only when the E velocity ends
before the onset of QRS
IVRT ,65 ms Nagueh, 199693 Rather poor reproducibility
Pulmonary venous flow DDT ,150 ms Matsukida, 200195
Chirillo, 199797
A value .220 ms suggests normal LV filling pressure
E/e′ ≥11 Sohn, 199998 Septal e′ was used in this study
E/Vp .1.4 Nagueh, 199693 Limited clinical value because of reproducibility
EDT, E-wave deceleration time; IVRT, isovolumic relaxation time; DDT, D-velocity deceleration time; E/e′ , the ratio of mitral E to TDI-derived early diastolic myocardial velocity;
E/Vp, the ratio of mitral E to colour M-mode flow propagation velocity.
EACVI/EHRA Expert Consensus Document 363
Downloaded from https://academic.oup.com/ehjcimaging/article-abstract/17/4/355/2464865
by Belgrade University user
on 13 March 2018
1.7 RV function
While the relationship between the dimension and the function of
the RA and AF is properly documented, there are poor data about
the RV function in patients with AF, although the importance of
heart rhythm for RV function is well known. Moreover, atrial ta-
chyarrhythmias are most common in patients with depressed RV
function and their occurrence may be one of the clinical
manifestations of RV failure. Atrial flutter or AF may also cause
haemodynamic compromise and worsen prognosis in patients with
RV failure.104,105
Ventricular interdependence implies the fact that dysfunction of
both ventricles often co-exist, mainly dependent on the function
of the intraventricular septum: LV failure can lead to RV dysfunction
and, on the other hand, RV failure aggravates the prognosis of
Figure 5 Example of (A) the measurement of LA volume; (B) the measurement of RA volume in TTE.
Figure 6 Example of LA strain curves in a normal patient (A) and in a patient with AF (B).
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patients with dysfunctional LV.106 Cohen et al.107 demonstrated, in
patient with AF, the relationship between echocardiographic indices
of RV systolic and diastolic function [tricuspid annular plane systolic
excursion (TAPSE), e′] and LV diastolic function. Doppler measure-
ments of RV function (s′, e′) also correlated with functional capacity,
calculated through 6MWT. All these data underline the importance
of a complete evaluation of RV function during an echocardiograph-
ic examination, particularly in AF patients.
There are several measurements that can be employed:
– End-diastolic basal and mid-cavity RV diameters that are dimen-
sional data useful to evaluate RV dilatation in response to volume
or pressure overload. It is equally important to assess whether
D-shape pattern of ventricular septal curvature is present as a re-
sult of dilatation of the RV;
– Two-dimensional fractional area change (RVFAC), defined
as (end-diastolic area 2 end-systolic area)/end-diastolic
area × 100, is an index of systolic function that has been
shown to correlate with RVEF by magnetic resonance imaging
(MRI);108
TAPSE is a simple, less dependent on optimal image quality, and re-
producible index of RV longitudinal systolic function. It is very feas-
ible and reliable even in patients with AF; TAPSE should be used
routinely as a simple method of estimating RV function, with a lower
reference value for impaired RV systolic function of 16 mm.
– Tissue Doppler imaging enables measurement of peak systolic
velocity of the tricuspid annulus (s′) which is another comple-
mentary method for evaluating RV longitudinal function at RV
base.
The parameters used to assess RV diastolic function are essentially
similar to those used to assess the left side. Lang et al.40 reported
extensively on that subject. Tricuspid E/e′ . 6 is in favour of an in-
crease in right atrial pressure. Tricuspid e′ , 7.8 cm/s evokes a right
heart diastolic dysfunction.
2. Advanced echocardiography
Not mandatory yet but very promising tools to implement in clinical
practice.
2.1 Speckle tracking
Assessment of atrial function with conventional approaches could
be challenging and imperfect. Transmitral flow velocity with pulsed
Doppler imaging shows the flow velocity due to atrial contraction.
This can be used to measure atrial force, an indirect measure of at-
rial function.23 Unfortunately, the A-velocity is absent in AF, re-
covers gradually after successful electric cardioversion, and is
highly dependent on loading conditions and LV diastolic and systolic
functions. Thus, the A-velocity is a limited tool for assessing atrial
mechanical function. Another way of assessing atrial function is to
measure the LA emptying fraction. In sinus rhythm, atrial emptying
comprises both passive (conduit) and active (atrial contraction or
atrial booster pump function) phases. In AF, there is only a passive
phase, hence the term ‘emptying fraction’ rather than ‘ejection frac-
tion’. Myocardial mechanics by strain imaging, which is widely used
to assess ventricular function, has also been applied to assess atrial
function in a few studies (Figure 7).109
Cameli et al.47 measured LA longitudinal strain by speckle tracking
and reported a global LA strain of 42%. But that cut-off value cannot
necessarily be applied for all studies. The different vendors use
Figure 7 Presentation of the two techniques currently proposed for measuring LA strain. The difference is based on the definition of the start of
the analysis at the R-wave (A) or the P-wave (B) of the ECG.
EACVI/EHRA Expert Consensus Document 365
Downloaded from https://academic.oup.com/ehjcimaging/article-abstract/17/4/355/2464865
by Belgrade University user
on 13 March 2018
different algorithms in their speckle tracking techniques. For in-
stance, VVI tracks the motion of mitral annular plane in addition
to speckle tracking to generate strain curves. Other software are
just speckle tracking originally developed for assessment of LV func-
tion and then used for assessment of the atrial function, without fur-
ther validation studies. Differences in these techniques probably
result in different values for strain and strain rate in normal subjects
and patients. The very thin LA wall poses challenges to pure speckle-
tracking techniques. An effort of standardization for assessment of
LA function by speckle tracking is therefore needed from the differ-
ent manufacturers.110 The acquisition should also be standardized;
using the zoom mode, define the optimal frame rate and agree on
a standardized reference point. The ECG-derived R-wave is usually
the reference point for the assessment of the LV function, but it
might generate different strain than a study performed using the
P-wave as ‘reference zero’ value (for instance, normal value of res-
ervoir function ¼ 46.8+7.7% for Sun et al. using the R-wave as ref-
erence and 21.4+ 6.7% for Saraiva et al. using the P-wave.111,112
The use of the P-wave is nevertheless limited by its non-applicability
to patients in atrial arrhythmia (Figure 7).
Studies on a larger population comparing the different ap-
proaches are needed to provide standard or reference values. Kup-
pahally et al. demonstrated that LA fibrosis by cardiac magnetic
resonance (CMR) has significant correlation with mid-lateral strain
and strain rate, independent of other LA size measurements.113 The
mid-septal area is probably not the area that one has to measure
when compared with mid-lateral LA strain because this region is
thin and also because of the presence of fossa ovalis or septal aneur-
ysms. The filling pressure in the RA can influence its movement.
Nevertheless, most studies have used the average atrial strain with-
out considering the regional strain curves generated by software.
Large population series will have to be conducted to define nor-
mal values and values associated with the risk of AF, stroke, or HF.
Using CMR approach, and using the MESA cohort, a recent study
demonstrated that LA longitudinal strain might be an independent
predictor of development of HF in asymptomatic individuals. Also
with a cut-off point of 25.8%, LA GLS can predict the existence of
a paroxysmal AF in a stroke population with sensitivity of 70% and
specificity of 75%. In an observational study, LA strain has also been
demonstrated to provide incremental diagnostic information over
that provided by the CHA2DS2-VASc score, suggesting that LA
strain analysis could improve the current risk stratification of embol-
ism in patients with AF.114
LA contraction, which is seen as negative strain and strain rate, is
absent in AF. LA relaxation or peak lengthening strain during ven-
tricular systole, represented by positive strain and strain rate, are im-
portant indicators of LA compliance or reservoir function that is
impaired in AF caused by fibrosis. Blunted atrial strain was demon-
strated to not be directly related to elevation of LV filling pressure
(as assessed by the E/e′ ratio).
Also, one can keep in mind that from the LV function perspec-
tive, LV GLS has been reported to be an independent prognostic
marker in patients with persistent AF referred for echocardiog-
raphy. In this study, GLS was a major parameter and stronger pre-
dictor of adverse cardiovascular events than LVEF or pulsed tissue
Doppler.86
Key point 8
(1) The LA lateral wall strain can be reliably imaged and is not
constrained by other cardiac chambers and may be used as the
best surrogate of LA wall fibrosis by CMR.
(2) A LA strain (in systole) ,30% indicates significant alteration
of LA reservoir function, which predicts the poor outcome.
Key point 9
LA should be measured form the R-wave of the ECG in AF. The
beginning of the P-wave should be preferred in sinus rhythm.
2.2 Three-dimensional echocardiography
Evaluation of the LA volume is important, as it is a marker of cardio-
vascular disease and outcomes and correlates with LV diastolic dys-
function severity. LA volume measurements, by different imaging
modalities (including 2D and 3D echocardiography (2DE and
3DE), are not interchangeable. Although 2DE underestimates LA
volumes, most normative as well as predictive data have been ob-
tained using this modality. Standardization, with established norma-
tive data and classification criteria, needs to be established for other
imaging modalities, additionally incorporating assessment of LA min-
imum and phasic volumes. Despite the limitations of the more sim-
plistic 2DE (relies on geometric assumptions regarding the LA
shape), its measurements are well defined with a significant prog-
nostic value and still has to be promoted instead of the LA diameter
got from the parasternal long-axis view. The incremental prognostic
value of the more complex imaging techniques needs to be further
validated. The available data have to be considered and the im-
proved workflow of echocardiographic platforms will facilitate its
outspreading.115,116
Real-time 3DE is free of assumptions and accordingly an attractive
alternative for the evaluation of LA volume. The best validation we
have for the 3D approach of direct measurement of LA volume in-
cludes 92 patients with a wide range of it. Patients underwent CMR
(1.5-T) and echocardiographic imaging on the same day. 2DE images
were analysed by the biplane area– length technique and 3DE
images by TOMTEC LA Function software.117 3DE-derived LAV
measurements were more accurate than 2DE-based analysis, result-
ing in fewer patients with undetected atrial enlargement when com-
pared with the CMR reference. Inter- and intra-observer variabilities
of 2DE and 3DE measurements of maximal LA volume were similar
(7–12%) and approximately two times higher than CMR. Another
relevant study included 556 patients with high prevalence of cardio-
vascular disease. After excluding patients with AF, because (except
for one echo-machine) 3D volumes are requiting an acquisition on
4–6 cardiac beats. Four hundred and thirty-nine subjects were fol-
lowed up to record major adverse cardiovascular events. It was de-
monstrated that indexed LA volumes (LAVIs) by both 2DE and 3DE
are powerful predictors of future cardiac events. Of notice, 3D
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mininum LA volume tended to have a stronger and additive prog-
nostic value than 3D maximum LA volume.61
Key point 10
Assessment of LA volumes by 3D echocardiography will have to
be implemented in clinical practice. It is still not available widely,
but it has been demonstrated as really valuable. Like LV volume
by 3D echocardiography, it has been proposed as superior to the
2D approach that remains the standard approach.
2.3 Imaging of the LAA
3D is now the standard method of TOE in many echo laboratories.
The 3D volumetric and multiplan TOE provides a new window on
the complexity of the LAA architecture (Figures 2 and 3). Precise
knowledge of LAA orifice size is crucial for correct sizing of LAA
closure devices; it will be developed in an upcoming chapter. The
implantation of these devices required 3D TOE. Also, patients
with a history of stroke had larger LAA mean volumes than control
subjects (28.8–13.5 vs. 21.7–8.27 cm3, P ¼ 0.002). Stroke risk is
highest in patients with an LAA volume of .34 cm3 (multivariable
OR 7.11, P ¼0.003). In conclusion, larger LAA volume is associated
with stroke in patients with AF, and this measure can potentially im-
prove risk stratification for stroke risk management in AF patients.
As mentioned later, specific 3D guiding is needed for correct posi-
tioning of the guide catheter inside the LAA and following the ex-
pansion of the occluder.118
3. Cardiac magnetic resonance
Histological studies have demonstrated proliferation of myofibro-
blasts and variable levels of collagen deposition in the LA myocar-
dium of patients with AF.119 LA tissue fibrosis is associated with
anisotropy, with changes in electrical activation (reduction in myo-
cardial voltage and decrease in the effective refractory period) and is
thus considered a substrate perpetuating AF.120
The term fibrotic atrial cardiomyopathy is describing a specific, pri-
mary form of biatrial pathology, characterized by extensive fibrosis as
the substrate underlying atrial arrhythmias and thromboembolism.87
Technical aspects of CMR in atrial fibrotic tissue
characterization
Late-gadolinium enhancement (LGE) CMR is the established meth-
od for visualizing, in vivo, myocardial tissue fibrosis within cardiac
ventricles121 (Figure 8). However, standard LGE CMR is challenged
by the thin-walled atrium. An important step towards assessing atrial
fibrosis using CMR has been achieved with the advent of a 3D
respiratory-navigated sequence allowing improved spatial reso-
lution.122 Unlike standard LGE CMR, this free-breathing sequence
is not limited by breath-hold duration and thus allows coverage of
the whole atrium using a 1.25×1.25×2.5 mm voxel size. LA fibrotic
changes are visible as thin areas of delayed enhancement along the
LA wall. Subsequent image post-processing allows quantification of
LGE areas. It generally includes two steps: (i) segmentation of LA
wall voxels using slice-by-slice manual contouring of epicardial and
endocardial borders and (ii) segmentation of enhanced LA
myocardium (i.e. LA tissue fibrosis) from the histogram of LA wall
voxels using a threshold-based algorithm. The resulting segmented
volume is then displayed, either qualitatively through a rendered 3D
model of LA showing the spatial extent of LGE or quantitatively as a
percentage of LA volume.
However, high-resolution LGE CMR of atrial fibrosis remains
technically challenging and the post-processing is fairly time-
consuming (up to 1 h per patient).
In the multicentre prospective DECAAF study,123 17% of LGE da-
tasets were excluded due to poor quality images related to CMR
technologist error or patients arrhythmia during acquisition. An al-
ternative approach based on the quantification of LA extracellular
volume fraction by T1 mapping technique was recently pro-
posed.124 T1 relaxation times measured in LA posterior wall were
shorter in patients with AF than in controls, thereby suggesting that
T1 value might be a surrogate for diffuse interstitial LA fibrosis bur-
den. However, these preliminary results need further confirmation,
especially given the limitations of the T1 mapping technique in terms
of accuracy and reproducibility.125
Impact of pre-ablation LGE CMR on AF recurrence
Oakes et al. have shown that LA fibrotic remodelling identified by
LGE MRI is positively correlated with the likelihood of recurrent ar-
rhythmia following catheter ablation.126 Other studies from the
same group have further documented the link between pre-ablation
LGE and poor outcomes of AF catheter ablation.127,128 These re-
sults have been confirmed by the multicentre DECAAF trial in
which 329 patients prospectively underwent LGE MRI within 30
days before AF catheter ablation.123 The authors categorized pa-
tients into four groups according to the extent of pre-ablation
LGE: stage 1 (atrial fibrosis burden,10%), stage 2 (10–20%), stage
3 (20–30%), and stage 4 (.30%). The cumulative incidence of AF
recurrence at day 475 after ablation was 15% for stage 1, 36% for
stage 2, 46% for stage 3, and 69% for stage 4. These results suggest
that the degree of LA fibrosis quantified by LGE CMR might be used
to stratify recurrence risk and therefore personalize the therapeutic
Figure 8 Example of a CMR with the LGE within the LA walls
(arrows).
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strategy to each patient (i.e. to decide medical management vs. cath-
eter ablation, and if so to tailor ablation strategy to LGE imaging).
Atrial fibrosis has also shown to be significantly and independent-
ly associated with the risk of LV systolic dysfunction,129 with LAA-
thrombus formation,130 and with the risk of stroke.131 A better
knowledge about the impact of fibrosis on atrial electrical activity
may allow identifying new ablation targets in persistent AF. Several
studies have investigated the relationships between LGE CMR and
endocardial mapping.126,132 – 136 All of those have reported a strong
spatial agreement between enhancement areas on LGE CMR im-
aging and low-voltage regions on electroanatomic maps. In addition,
Jadidi et al. have studied the relationships between atrial fibrosis at
LGE CMR and electrogram characteristics from high-density map-
ping in 18 patients with persistent AF.133 The authors categorized
atrial tissue into dense LGE areas, patchy LGE areas, and non-LGE
(i.e. normal) areas. They found an inverse relationship between at-
rial fibrosis and electrogram fragmentation, with more complex
fractionated atrial electrograms in patchy and non-LGE areas, and
more organized electrical activity in dense LGE areas. These results
might have an impact on ablation strategy. Also, the fusion of LGE
CMR imaging with body surface ECG mapping might be a promising
way to study the relationships between atrial fibrosis and reentrant
AF drivers.137
In regard to the potential role of post-ablation LGE CMR
Hunter et al. have recently concluded that LGE CMR is not yet
sufficiently accurate to reliably assess post-ablation lesion distribu-
tion.138 Moreover, LGE imaging does not seem to provide accurate
information on the location of pulmonary veins reconnection sites
in patients undergoing repeat ablation for AF.136
Key point 11
Up to now, there is neither recommendation nor expert consensus
on the role of LGE CMR to assist AF ablation procedures.
The available data are intriguing enough to warrant further
research.
4. Computed tomography (CT)
Cardiac computed tomography (CT) imaging is increasingly being
implemented in clinical routine due to advances in technology offer-
ing higher spatial and temporal resolution and hence better diagnos-
tic image quality. Indications for cardiac CT imaging extend beyond
assessment of CAD and risk stratification to the use in structural
heart disease for pre- and post-procedural assessment of patients
referred for several percutaneous interventions. More importantly,
the increasing use of acquisition modes with prospectively
ECG-gated trigger have led to a significant reduction in effective
radiation doses compared with retrospective acquisition modes.
In a meta-analysis of 3330 patients, the pooled effective radiation
dose for prospectively gated examinations was reduced by a factor
of 3.5 compared with retrospective gating (3.5 mSv) compared with
12.3 mSv for retrospective gating, P,0.01).139 While imaging of the
pulmonary venous anatomy prior to pulmonary vein isolation is
possible using non-gated CT acquisitions, recent advances in CT
scanner technology allow for low-dose ECG-triggered acquisitions
with far superior image quality compared with non-gated-exams.
Also, imaging of the pulmonary veins is done using the very routine
contrast timing used for a usual cardiac CT.
4.1 Epicardial adipose tissue (EAT) and AF
In the past decade, there has been growing interest in ‘cardiac adi-
posity’ and its relationship to cardiovascular disease. Epicardial adi-
pose tissue (EAT) refers to visceral fat enclosed within the
pericardial sac, and in direct contact with neighbouring cardiac
structures. Several imaging modalities such as echocardiography,
CT, and CMR can be used to quantify epicardial adipose tissue. Ow-
ing to its high spatial resolution and true volume coverage of the
heart, CT (and potentially CMR) provides an attractive modality
to quantify epicardial adipose tissue. An increasing body of evidence
has been accumulated, which demonstrates a relationship between
EAT and coronary atherosclerosis, cardiovascular outcomes, and
heart disease such as AF.140,141 The association of increased epicar-
dial adipose tissue with cardiac disease remains significant even
after correction for weight, body mass index, and traditional
cardiovascular risk factors. The mechanisms have not been reliably
identified, but metabolic properties of epicardial fat seem to play a
role.140,141 Obesity is increasingly being recognized as a risk factor
for the increasing burden of AF.140,142 –144 Whether localized car-
diac ectopic fat rather than traditional measures of obesity is
more predictive of cardiovascular disease and AF burden has
been a field of intensive research over the past years. Currently,
quantification of epicardial adipose tissue is not included in recom-
mended algorithms for risk stratification.
Key point 12
Further studies investigating the association atrial arrhythmia and
epicardial adiposity are needed. No real clinical impact is demon-
strated yet.
4.2 Geometry of LAA: implications for transcatheter
closure
Percutaneous interventional closure of the LAA has emerged as an
alternative therapy for reduction of embolic stroke in patients with
non-valvular AF and contraindications to oral anticoagulation, and
has been shown to be comparable with standard warfarin treatment
in reducing thrombo-embolic events.145,146
Device sizing is based on TOE, angiographic measurements as
well as 3D imaging modalities. 3D imaging using CT provides com-
plete volumetric evaluation of the LAA and its spatial orientation to
important neighbouring structures, including the MV and the pul-
monary veins. Detailed assessment of the ostium of the LAA with
its spatial surrounding is essential for correct sizing and procedural
success. Several studies using 3D imaging techniques have reported
on the morphology of the LAA in a descriptive fashion.147 – 150
Terminology as ‘chicken wing’, ‘windsock’, ‘cactus’, and ‘cauli-
flower’ have been used to describe the LAA morphology. Recently,
a study classifying LAA morphology based on the assessment of post-
mortem specimens as well as CT imaging in patients referred for
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LAA occlusion has been published.151 The authors classified the LAA
into three types according to specific anatomical features, and fur-
ther evaluated the relation between different LAA morphologies
to procedural success and difficulties. LAA was classified according
to the level of the ostium, thickness, and width of the left lateral ridge,
anatomy of the zone extending between the ostium and the left lat-
eral ridge and the distance to the MV.152 Appendages in close prox-
imity to the ‘LA floor’ were described from an interventional stand
point to be the most difficult to occlude, due to the difficulty of co-
axially aligning the delivery catheter with the long axis of the LAA.151
This anatomical information can be provided by CT and not totally
by TOE or angiography and may alert operators to use a lower septal
puncture or a different delivery catheter.151
Furthermore, patients with broader left lateral ridge provide an
appropriate landing zone for the occluder device in contrast to pa-
tients with narrower ones, in whom compromise of the pulmonary
veins could be caused by encroaching devices. Moreover, other ana-
tomical considerations increasing the complexity of the procedure
include bilobular appendages and appendages with early branching
and absence of an adequate ‘landing zone’.151 In addition, the ellips-
oid nature of the LAA ostium as well as the complexity of defining
the borders of its orifice may lead to discrepancies in ostial mea-
surements using different imaging modalities. CT offers an accurate
modality capable of defining the orientation of the LAA and subse-
quently providing cross-sectional measurements of the LAA ostium
strictly orthogonal to its long axis. The use of CT imaging is not lim-
ited to pre-procedural planning, assessment of device position,
complete occlusion of the LAA and device-related complications
such as thrombosis and para-device leak could be assessed by CT.
4.3 CT imaging before and after catheter ablation
Morphological considerations
Catheter ablation with pulmonary vein isolation is an established
treatment option for symptomatic patients with drug-refractory
paroxysmal or persistent AF.11 Detailed anatomy of the LA pulmon-
ary veins and neighbouring structures can be easily provided using
CT imaging and is important for procedural planning and to help
minimize the risk of complications.153,154 The number of pulmonary
veins, pattern of branching, ostial morphology and measurements,
and more importantly anomalous pulmonary vein variants, acces-
sory pulmonary veins, or anomalous pulmonary venous drainage
can be easily identified by CT compared with other modalities
such as TOE and ICE.154 – 157 Spontaneous echo contrast was
more commonly diagnosed with ICE (P, 0.01). ICE imaging is an
alternative to TEE for visualization of the LAA and RAA during cath-
eter ablation procedures.158
All the more, 3D reconstructions depicting the complex LA and
pulmonary venous anatomy provide important information that
may guide the operator in catheter selection and approach for the
procedure (Figures 9 and 10).154 While TOE remains the gold stand-
ard for the detection of LAA thrombi prior to ablation procedures,
several studies have shown a high diagnostic accuracy of CT to de-
tect LAA thrombi. An adequate scan algorithm with a late pass scan
has to be performed. The diagnostic accuracy for detection of LAA
thrombi was reported to be 99% in a meta-analysis of studies using
delayed imaging protocols.159 These modified scan algorithms im-
prove the diagnostic accuracy of thrombus detection, which is
usually hampered in early scan phases by delayed contrast filling
of the LA appendage in patients with AF.
However, according to the expert consensus statement for cath-
eter and surgical ablation published in 2012, the use of cardiac CT to
exclude thrombi of the LAA in patients with high risk of stroke is not
recommended.160 Furthermore, spatial orientation of the LA and
the pulmonary veins to the oesophagus can be easily identified
and is beneficial in risk reduction of lethal complications such as
atrio-oesophageal fistula caused by high-energy application during
ablation procedures.153,154 Pulmonary vein stenosis is nowadays
an infrequent, yet known complication following catheter ablation
procedures.161,162 In patients with symptoms suggestive of pulmon-
ary venous obstruction, serial CT assessment of pulmonary veins al-
lows for detection or exclusion of stenosis.154 Due to the wide
variation in pulmonary venous anatomy, acquisition of a pre-
procedural scan for comparison purposes is important especially
to detect cases with only mild-to-moderate stenosis that may pro-
gress with time.
Integration of CT anatomy and electro-anatomical mapping
The introduction of 3D electro-anatomical mapping systems has led
to a new era in catheter ablation procedures. Data acquired from
electrical mapping of the left atrium are used to render a 3D geo-
metrical map of the left atrium. However, these maps are operator-
dependent and are subject to anatomical inaccuracies.163 Techno-
logical advances has allowed for fusion of pre-procedural CT images
either direct into fluoroscopy or into electro-anatomical mapping
systems providing 3D depiction of individual patient anatomy.163
The static nature of the CT images as well as the time lag between
CT acquisition and the ablation procedure with subsequent change
in volume status and potentially rhythm status are acknowledged
limitations for such fusion modalities. Furthermore, data evaluating
patient outcomes’ after catheter ablation procedures with and with-
out integration of pre-procedural CT anatomical data are contro-
versial.163 – 167 Whether the use of such fusion technologies
translate into better patient outcomes remains questionable and
need to be assessed in future prospective studies (Figure 10).
D. Specificity of the imaging
assessment of AF patients
1. Cases of the valvular heart diseases
1.1 MV disease
Echocardiography plays an essential role for the diagnosis and
follow-up of patients with MV disease and AF, guiding both the tim-
ing and the type of intervention.
It is well known that valvular heart diseases, and particularly those
involving the MV, are associated with AF;168 however, the precise
rate of association of AF and organic MV disease has been variably
reported with a relationship between LA size and the incidence of
the arrhythmia. In the largest series reported in patients with degen-
erative mitral regurgitation (MR), AF was a common complication if
patients were managed conservatively, occurring at a linearized rate
of 5% per year and the risk increased with advancing age.169 The on-
set of AF was independently associated with an increased risk of ad-
verse cardiac death and HF. Indeed, AF is considered a risk factor of
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worse outcome in patients with either mitral stenosis or regurgita-
tion and is considered as a possible indication for intervention even
in asymptomatic patients (classes IIa and IIb, level of evidence
C).170,171 Additionally, AF is associated with a certain degree of func-
tional MR due to annular dilatation and loss of atrial contraction,
which is mild or moderate in most of the cases and secondary to
the arrhythmia and the associated cardiac remodelling.172
The main contributions of cardiac imaging in patients with MV dis-
ease and AF are summarized in Table 3. Echocardiography remains
the imaging technique of choice to quantify MV dysfunction. Mitral
stenosis severity is typically quantified either by the use of the pres-
sure half-time formula or direct planimetry, with severe stenosis
being considered in estimated valve areas of ,1.5 cm2; other meth-
ods such as flow convergence or PISA and quantitative Doppler can
also be used. The addition of transvalvular pressure gradients calcu-
lated with CW Doppler contributes to the diagnosis. The main limi-
tation of area estimation and gradient calculation among patients
with AF is the variability in the R–R cycle due to the different ven-
tricular rate response as well as high heart rates. The former can be
minimized by averaging several cardiac cycles (at least 5) in patients
with variable R–R lengths; the latter is more difficult to overcome
but one has to keep in mind that transvalvular gradients increase
with tachycardia due to shortening of the diastolic time and not ne-
cessarily due to more severe valve stenosis; valsalva manoeuvre or
pharmacological treatment to reduce ventricular rate response
(ideally ,80 bpm) might be of help to improve the accuracy of
Doppler-echo-based measurements. Three-dimensional echocardi-
ography planimetry has shown the best agreement with invasive
methods to determine the stenotic MV area.173 Although a few
studies have shown its potential use to estimate mitral stenosis se-
verity, MSCT and MRI studies are rarely used for this only purpose
(Table 3).
In patients with AF, quantification of MR with the PISA method
based on 2D echo is recommended and widely used, like in other
conditions. A more detailed review of the different methods to
quantify MR is reported elsewhere.174
Echocardiography also provides information about the morph-
ology of the valve which is essential to evaluate the suitability for
Figure 9 Algorithm of the role of imaging modalities in the process of AF ablation.
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percutaneous balloon valvuloplasty. In this sense, 3D echocardiog-
raphy provides a unique comprehensive analysis of the whole
geometry of the valve and has been shown to be feasible and useful
in the assessment of residual stenosis and regurgitation
before, during, and after a percutaneous balloon valvuloplasty
procedure.72,175,176
1.2 Aortic valve disease
In guidelines, atrial arrhythmias are not proposed as significant
events that might impact the treatment strategy. The prevalence
of AF is lower in aortic valve disease than in MV diseases. In Rennes
surgical database, according to more than 4000 patients assessed for
aortic valve replacement, about 10% are in arrhythmia before
surgery and about 15% will have atrial arrhythmia episode in the
early post-operative period. These have more co-morbidities, an
history of renal failure, stroke, etc.; thus, they have an higher Euro-
SCORE. In PARTNER A (40%) and in FRANCE-2 (25.5%) the preva-
lence of arrhythmia is higher than in surgical cohorts.177 –179
AF is more prevalent in low-flow, low-gradient, preserved LVEF
patients. That is in part related to the co-morbidities but it is im-
portant to keep in mind that this arrhythmia complicates the as-
sessment of the severity of the aortic stenosis (AS) as it would
complicate the assessment of the degree of aortic regurgitation.
The ventricular irregularity requires averaging several consecutive
gradients and the calculation of the effective orifice area is compli-
cated as well except if the continuous Doppler tracing provide a
Figure 10 (A) Multiplanar reconstruction of a CT dataset of a 55-year-old female patient with paroxysmal AF prior to pulmonary vein isolation.
LA segmentation rendered using semi-automatic dedicated software with the arrow pointing at an accessory right middle pulmonary vein. (B) 3D
volumetric reconstruction using the same software with the left atrium viewed from an anterior and caudal plane.
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Table 3 Contribution of cardiac imaging in patients with AF and MV disease
TTE TOE MSCT CMR
Quantification of mitral valve dysfunction +++
includes 3DTTE
+++
includes 3DTTE
2 +
Functional anatomy of the MV:
suitability for repair (percutaneous or surgical)
++
includes 3DTTE
+++
includes 3DTTE
+
Calcium
+/2
Haemodyamic impact of MV dysfunction (ventricular
volumes and function)
++
includes 3DTTE
+ + +++
Evaluation of LA size, geometry, function and fibrosis +++
includes 3DTTE and strain
+
includes 3DTTE
+ +++
Rule out complication of AF and MV disease:
LAA thrombus
2 +++ ++ ++
Guiding intervention: percutaneous or surgical +
includes 3DTTE
+
includes 3DTTE
2 2
Relative contribution of each technique: 2 none, + useful, +++ most useful.
AF, atrial fibrillation; LA, left atrial; LAA, LA appendage; MV, mitral valve; TTE, transthoracic echocardiography; TOE, transoesophageal echocardiography; MSCT, multi-slice
computed tomography; CMR, cardiac magnetic resonance.
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clear trace of the LV outflow tract flow and a clear trace of the
trans aortic valve flow.
Interestingly, in the years following the surgery, about 40% will
present an atrial arrhythmia episode. Also it has been reported by
Pilgrim et al.180 that in patients with a severe AS, independent prog-
nostic markers for death were: body mass index ≤20 kg/m2,
diabetes, peripheral vascular disease, and AF, in addition to pulmon-
ary hypertension. Therefore, in the population of patients proposed
for a percutaneous treatment of the AS, the prevalence of atrial ar-
rhythmia is greater than in surgical cohort.181 AF has an independent
prognostic value independently of the quality of the aortic prosthet-
ic valve implantation.182 For the TAVI population, Stortecky et al. re-
ported that AF is associated with a two-fold increased risk of
all-cause and cardiovascular mortality among patients undergoing
TAVI at 1-year follow-up.181
1.3 Right heart valve disease
Data in the literature are scarce, but in patients with AF, there is a
progressive increase in the RA size and pressure. That leads to an
enlargement of the tricuspid annulus. Contemporarily, elevated
LA pressure might increase the RV afterload. All these phenomena
may lead to a functional tricuspid regurgitation that will increase by
participating in this vicious cycle.183
2. Detection of myocardial ischaemia
in patients with AF
2.1 Stress echocardiography
As coronary disease and AF can coexist, patients with AF are often
referred for stress echo to assess myocardial ischaemia or viability,
in the context of existence of symptoms of angina or HF. In the ab-
sence of such symptoms, there is no evidence to support the use of
stress echo for the assessment of aetiology of new onset AF.184
More so, AF can develop during stress echo as a complication of
the test185 in patients with or without a history of paroxysmal AF.
The assessment of wall motion abnormalities in AF patients:
reliable or not?
AF can impact regional LV-systolic function assessment, resulting in
both false-positive and false-negative results. Furthermore, in AF,
the heart rate may rise excessively at low workload, during either
dobutamine stress echo or exercise echo, resulting in low sensitivity
of the test, with higher likelihood of false-negative results, which
does not seem to alter the prognostic value of the test.186
False-positive results may be due to LV systolic dyssynchrony in-
duced by tachycardia-related aberration with bundle branch block
morphology of ECG complexes and consequent delayed myocardial
activation resulting in delayed contraction. More so, even in the absence
of aberration, extreme tachycardia may simply make the interpretation
of results difficult, despite the use of heart rate synchronization in be-
tween stages on the stress echo template, restricting both the specifi-
city and the sensitivity of the test. Particularly, if the cardiac cycle
assessed is preceded by a short cardiac cycle, implying short diastole re-
sulting in limited LV cavity filling and consequent limited contraction in
the cardiac cycle assessed, the limited endocardial excursion makes it
more difficult to detect regional wall motion abnormalities.
The beat-to-beat variation of the cardiac cycle length results in
specific pitfalls. The beat-to-beat variation renders the recognition
of regional wall motion abnormalities during the test difficult. To
overcome this, image acquisition should avoid both extremely short
and extremely long cardiac cycle length, selecting a cardiac cycle
which is representative of the actual average heart rate.
2.2 The choice of the stressor
With appropriate precautions, any stressor can be generally used
successfully and safe in AF. The stress echo report should mention
the workload achieved and declare the low sensitivity of the test in
case of early termination due to excessive tachycardia.
Occasionally, the patients present for a dobutamine or exercise
stress echo with tachycardia at rest, because of discontinuation of
heart rate-limiting drugs.185,187
In this case, the test may be rearranged on heart rate-limiting drugs.
Dobutamine and exercise echo have a lower sensitivity when per-
formed without discontinuation of heart rate-limiting drugs. Alterna-
tively, adenosine or dipyridamole stress echo may be performed using
myocardial contrast echocardiography-based myocardial perfusion
assessment188,189 to improve the diagnostic value of the test com-
pared with assessment of regional wall motion only.
2.3 Nuclear cardiology techniques
In recent years, the functional relationship between the occurrence
of AF and the presence and extent of myocardial ischaemic heart
disease has been investigated.190 However, the existence of a patho-
physiological interaction between these two affections has not been
conclusively demonstrated.191,192
Independently of the presence of CAD, a consistent association
among AF and the development of significant alterations of myocar-
dial blood flow regulation at myocardial perfusion imaging (MPI) has
been suggested.190 – 192 As a matter of fact, the presence of AF has
been shown to be significantly associated with relevant alterations
of global myocardial perfusion at cardiac-PET, as indicated by in-
creased coronary vascular resistances and diminished resting and
hyperaemic perfusion.190 This behaviour might explain angina-like
symptoms and diminished physical peak performance during AF.
Similarly, AF has been reported to significantly affect regional
myocardial perfusion heterogeneity at SPECT, diminishing MPI ac-
curacy in identifying the presence of ischaemia.191,192 These perfu-
sion abnormalities, only partially related to SPECT-related technical
limitations, i.e. unreliable gating, suggest a strong interaction be-
tween AF- and MPI-related diagnostic efficacies.
In a recent study, Gimelli et al.193 demonstrated that, despite the
overall strict correlation between the presence and extent of CAD
and myocardial perfusion and contractile impairment, the presence
of AF may significantly impact myocardial perfusion imaging accur-
acy in detecting significant coronary luminal narrowings. This dele-
terious association is independent from patients’ clinical and
functional variables, suggesting the existence of a causal link be-
tween AF and impaired MPI diagnostic accuracy.
In this study the presence of AF associated with a significantly
lower accuracy in detecting CAD that may depend on the type of
stress test used, pharmacological vs. exercise.
According to present and previous reports,194,195 the choice of
the vasodilator stress test might be preferable in order to maintain
diagnostic accuracy and avoid false-negative results.
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Key point 13
In patients with suspected ischaemic heart disease, the presence
of AF may substantially impair MPI accuracy in detecting signifi-
cant CAD. The interaction between AF- and MPI-related diagnos-
tic power was limited to patients submitted to an exercise stress
protocol and was related to a substantially lower exercise duration
and overall cardiac workload than in patients with sinus rhythm.
Therefore, while in the presence of AF a particularly careful evalu-
ation of patients’ clinical characteristics and ability to exercise
seems mandatory, the use of a vasodilator stress–test might be
preferred.
E. Multi-modality imaging (MMI)
approach for AF-treatments
1. Catheter ablation imaging
Pre-ablation
TTE is performed prior to an ablation procedure at the minimum to
detect or evaluate structural heart disease, measure the LA size or
volume, and assess systolic LV function (Figure 10).196
Since an LA thrombus is a definite contraindication for an AF
ablation procedure, pre-procedure TOE is commonly performed
to exclude an LA thrombus, and in many centres for all patients.
Consensus guidelines recommend a TOE if
– the patient has been in AF for 48 h or longer or
– for an unknown duration but without effective continuous antic-
oagulation for at least 3 weeks prior.
Performance of a TOE in patients who are in sinus rhythm at the
time of ablation or correctly treated by anticoagulants is not manda-
tory but is considered a useful additional precaution.160
Pre-procedure contrast-injected CT or CMR is used in many cen-
tres in order to evaluate LA and pulmonary veins size and anatomy
with precision. These image sets are then used for anatomical guid-
ance during the procedure.
Intra-procedural imaging
During the ablation procedure, TOE or ICE may be used to confirm
the absence of an LA thrombus before introducing catheters into
that chamber, to guide and confirm safe transseptal access to the
LA (typically in case of difficult or unusual anatomy or in the pres-
ence of inter-atrial septal occlusion devices), to guide and monitor
catheter placement at desired sites in the LA and at the LA–PV junc-
tion, to confirm occlusive placement of cryo-balloon catheters at PV
ostia and to maintain continuous surveillance for and provide early
warning of a developing pericardial effusion.
Echocardiographic screening is part of the evaluation of every pa-
tient presenting with hypotension, breathlessness, chest discomfort,
and/or symptoms of low cardiac output after catheter ablation of
AF.197 TTE screening for pericardial effusion after even uncompli-
cated catheter ablation of AF is performed in some labs.
If a pericardiocentesis is performed, periodic TTE are performed
to monitor response to, or to screen for re-accumulation of
pericardial fluid and/or timing of re-starting anticoagulation. After dis-
charge, a post-procedure Dressler-like syndrome, atrial tachycardia in
the setting of LV dysfunction or volume overload, and diastolic atrial
dysfunction (oedema after extensive atrial ablation) may all be part of
the differential diagnosis of breathlessness and echocardiography has
a key role in allowing the correct diagnosis and optimal treatment.
Intra-cardiac echocardiography
The technique has been used for more 10 years but still remain con-
fidential despite its great advantages as the decrease in use of the
fluoroscopy. The use of intra-cardiac echo can increase the safety
of transeptal puncture. It remains an expensive tool (2500E
the ICE catheter) that has been studied and demonstrated
useful.198 – 203 Its future is perhaps the new 3D probes that have
been developed, but no clear validation of their value for guiding
the treatment has been published (Figure 11).
Key point 14
Echocardiographic examination of pericardial effusion after cath-
eter ablation should only be performed based on symptoms and
clinical signs (i.e. drop in blood pressure).
Post-procedural imaging for prognosis and diagnosis
of the rare complications
In patients with pre-existing reduced LVEF and HF syndromes, it is
useful to perform TTE to monitor the evolution of LV function.
New parameters such as LA strain have been shown to predict
the rhythm outcome but may also provide prognostic rhythm infor-
mation following ablation.204,205
The occurrence of fever and/or a neurological deficit a week to 3
weeks after the procedure can result from an atrio-oesophageal fis-
tula formation and hence must not be ignored. A contrast-injected
thoracic CT scan is required to exclude the diagnosis. Electron
beam tomography has been described to visualize the LA oedema
associated with HF after extensive atrial ablation and both CT
as well as MR imaging may be useful to assess pericardial
pathologies.206
The onset of cough, haemoptysis, and dyspnoea weeks after the
procedure should suggest the possibility of pulmonary vein stenosis
and again a contrast-injected thoracic CT scan is typically diagnos-
tic.161,202,207 Routine CMR or CT for pulmonary vein stenosis 3–
6 months after an ablation procedure is no longer advised but
may be useful when using a new ablation device or technology or
in centres beginning to perform AF ablation procedures. A
ventilation-perfusion lung scan may be useful to screen for PV sten-
osis if CT and CMR are unavailable or to provide functional corrob-
oration of the severity of the narrowing.208,209
LGE CMR, T1 imaging, or CT perfusion imaging are all being eval-
uated for their ability to recognize atrial fibrosis and/or scar and may
be useful in patients with a recurrence after ablation to evaluate the
underlying scar and help develop an optimal management strategy
including planning repeat ablation. LA passive emptying fraction
evaluated by CMR may also provide prognostic information related
to rhythm outcomes.210
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The value of LAA morphological characteristics determined by
TOE but also CT or MR imaging as predictors of thrombo-embolic
events is currently under evaluation.211 – 214
Simple chest radiography may, of course, be of help to detect
pulmonary infection and/or broncho-aspiration. Post-procedural
dyspnoea due to phrenic palsy can be easily detected under fluoros-
copy by a ‘sniff test’.
2. Imaging in devices: LAA occluder
In patients with stroke of embolic origin, it is important to search for
a cardiogenic source of thromboembolism. Thromboembolism
typically arises from a clot in LAA in AF patients. Local therapeutic
alternatives to systemic anticoagulation involving surgical or percu-
taneous exclusion of the LAA have been developed. Occlusion of
the LAA using less invasive percutaneous, catheter-based methods
has been described since 2002.20 Preliminary studies of PLAATO
and WATCHMAN215,216 systems specifically designed for this
purpose has been completed. Both systems deploy a device
that is placed in the LAA through puncture of the interatrial
septum.152
Imaging plays an important role in this procedure, which is import-
ant for the LAA pre-procedural and peri-procedural assessment of
the LAA and for follow-up. The LAA can occasionally be visualized
with TTE but usually requires TOE, ICE, MRI, or CT23,217 (Figure 12).
Pre-procedural imaging
Pre-procedural echocardiography is used to screen suitable candidates
and to define the LAA morphology and dimension. It is very important
to confirm the absence of LAA thrombi prior to LAA occlusion. The
presence of mobile thrombi is a contraindication for the procedure.
However, LAA cannot be fully examined by TTE. In most patients,
the LAA can be adequately visualized using TOE. That is why, TOE
is claimed to be superior to TTE, and it is considered the reference
technique for the detection of thrombi in the LAA as well as examin-
ation of the anatomy and functions of the LAA before procedure.24
CMR seems to be another valuable visualization tool for the LAA
occluder implantation, which allows visualization of LAA and selec-
tion of the optimal LAA occluder size. CT scanning is an alternative
to ascertain the LAA anatomy, including its orientation and orifice
size in peri-procedural period.
Post-procedural imaging and follow-up
Post-procedural echocardiography is important in the surveillance
and monitoring of long-term outcomes. TTE is performed prior
Figure 11 Examples of the views that can be obtained by ICE. The septum, the veins can be precisely analysed.
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to discharge specifically to confirm device position and to exclude
pericardial effusion and thrombus around the device. It should also
confirm normal MV function and exclude LV dysfunction. Echocar-
diographic surveillance is currently recommended at 1 and 6
months, and annually post-procedure. TOE is the preferred im-
aging modality, although TTE may rarely be suitable in those indivi-
duals with good echocardiographic windows. Alternatively,
post-procedural imaging to assess device position, peri-device re-
sidual flow in the LAA, and thrombus formation on the device
consists of chest X-ray or CT. CMR is hampered by device
artefacts.218,219
The timing of a follow-up TOE varies between institutions. Most
operators use early or follow-up echocardiographic findings, i.e. the
absence of large residual flow into the LAA or thrombus, as a guide
for prescribing antithrombotic drugs.220
F. Areas for future researches
The prevalence of AF and still its complex management requires
new approaches. Current guidelines are population-based. The
next ones might become more patient-based (what is characterizing
an Afib in a patient and what are the risks and consequences asso-
ciated with that specific Afib). That means that for each individual,
the physician would be able to determine thanks to echocardiog-
raphy, CMR, and other techniques (including non-invasive electrical
mapping), how choosing between rate control and dedicated treat-
ment of the arrhythmia. It would be valuable also to be able to guide
the clinician in the sometimes challenging choice with regard to the
best anticoagulation regimen.
The ablation techniques have become increasingly sophisticated
and are already taking advantage of imaging techniques but one
can expect that the electro-mechanical coupling could be best as-
sessed and the treatment strategy individualized according to the
presence of low strain or extensive LGE.
High-frequency ultrasound imaging and new faster CMR se-
quences would probably allow a much better description of the ana-
tomical and histological properties of the atria (Figures 13–15).
Catheter ablation of AF without fluoroscopy is becoming feasible
and merits further attention. The 3D ICE is a new opportunity that
has to be tested. CMR is probably a valid alternative approach to
fluoroscopy.221,222 Catheter ablation under real-time MRI guidance
could be successfully carried out as a new technique.223
Figure 12 Example of an occluder in the left atrial appendage: TEE.
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Combination of advanced imaging techniques for simultaneous
tissue and catheter visualization, monitoring of ablation, and assess-
ment of the ablation lesions may be potential advantages over con-
ventional electrophysiology in the future (pre-operative planning of
the treatment, less invasive and individualized treatment and at the
end, non-invasive confirmation of the efficacy of the delivered
treatment).
Summary of the key messages
Key point 1: Measuring LA biplane volume, using either the
area– length or the discs formula indexed by body surface
area (BSA) is the method currently recommended for LA
size quantification. A normal LA volume is defined as ,34
mL/m2.
Key point 2: an echocardiographic examination is recom-
mended for every patient with AF to assess cardiac struc-
ture and function. An estimate of the degree of atrial
remodelling is important (value of indexed LA volume). In
addition, echocardiography can help to assess the risk of
LAA thrombus.
Past studies have used the theoretically simple measurement
of LA diameter using the para-sternal, long-axis M-mode ap-
proach. Nowadays, LA-indexed volumes should be preferred.
Key point 3: TOE is the most reliable test to rule-out the pres-
ence of an LAA thrombus before cardioversion of AF in non-
anticoagulated patients and in patients with past diagnosis of
LAA thrombus.
Key point 4: The absence of randomized study or large regis-
try demonstrating the prognostic value of imaging techniques
in AF patients is nevertheless a real weakness for echocardiog-
raphy and other imaging techniques.
Figure 13 MRI interventional suites—passive tracking of an
ablation catheter (ABL) positioned along the right atrial isthmus.
RA, right atrium; RV, right ventricle.
Figure 14 Active tracking of two electrode catheters positioned in the right atrium (RA; 1) and coronary sinus (CS; 2). The sequence A–D
depicts the transseptal access of catheter 1 into the left atrium (LA).
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Key point 5: In AF, the LV systolic dysfunction might be totally or
at least partially related to some degree of tachycardia-induced
cardiomyopathy. Usually in tachycardia-induced cardiomyopathy,
the LV is weakly or not enlarged.
Key point 6: In AF, the comprehensive assessment of LV
diastolic function and filling pressures required a combin-
ation of several parameters. Mitral annular early diastolic
velocity by pulsed tissue Doppler is a marker of LV diastolic
dysfunction, and septal e′ ,8 cm/s has a reasonable accur-
acy to identify LV delayed relaxation.
Key point 7: The normal range for 2DE RA volume index is
25+7 mL/m2 in men and 21+6 mL/m2 in women.40 RA vol-
ume.30 mL/m2 represents for sure a pathological enlargement
of the RA.
Key point 8: (1) The LA lateral wall strain can be reliably im-
aged and is not constrained by other cardiac chambers and may
be used as the best surrogate of LA wall fibrosis by CMR. (2)
An LA strain (in systole) ,30% indicates significant alteration
of LA reservoir function, which predicts poor outcome.
Key point 9: LA should be measured form the R-wave of the
ECG in AF. The beginning of the P-wave should be preferred in
sinus rhythm.
Key point 10: Assessment of LA volumes by 3D echocardi-
ography will have to be implemented in clinical practice. It is
still not available widely, but it has been demonstrated as real-
ly valuable. Like LV volume by 3D echocardiography, it has
been proposed as superior to the 2D approach that remains
the standard approach.
Key point 11: Up to now, there is neither recommendation
nor expert consensus on the role of LGE CMR to assist AF ab-
lation procedures. The available data are intriguing enough to
warrant further research.
Key point 12: Further studies investigating the association at-
rial arrhythmia and epicardial adiposity are needed. No real
clinical impact is demonstrated yet.
Key point 13: In patients with suspected ischaemic heart dis-
ease, the presence of AF may substantially impair MPI accuracy
in detecting significant CAD. The interaction between AF- and
MPI-related diagnostic power was limited to patients submit-
ted to an exercise stress protocol and was related to a substan-
tially lower exercise duration and overall cardiac workload
than in patients with sinus rhythm. Therefore, while in the pres-
ence of AF a particularly careful evaluation of patients’ clinical
characteristics and ability to exercise seems mandatory, the
use of a vasodilator stress–test might be preferred.
Key point 14: Echocardiographic examination of pericardial
effusion after catheter ablation should only be performed
based on symptoms and clinical signs (i.e. drop in blood
pressure).
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Cardiac amyloidosis: an unusual cause of low flow–low gradient aortic
stenosis with preserved ejection fraction
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Both low flow– low gradient aortic stenosis
(LFLG AS) despite preserved ejection fraction
(EF) and cardiac amyloidosis (CA) can be ob-
served in elderly patients with left ventricular
(LV) hypertrophy, apparently normal LV systolic
function but severe longitudinal dysfunction.
We report a case of a patient in whom the pat-
tern of LFLG AS was associated with and related
to an associated CA.
An 84-year-old man with hypertension and
permanent atrial fibrillation (AF) was referred
for congestive heart failure. Electrocardiogram
revealed AF and left bundle branch block.
Echocardiography found an increased LV wall
thickness (Panel A, Supplementary data online,
Videos S1 and S2). EF was 72%. Global longitudin-
al strain was –10.5%, with longitudinal dysfunc-
tion predominating in the basal segments with
apical sparing (Panel A). Aortic valve was heavily
calcified (see Supplementary data online, Videos
S3 and S4) with an LFLG AS pattern (mean
gradient ¼ 32 mmHg, stroke volume index ¼ 35 mL/m2, indexed aortic valve area ¼ 0.38 cm2/m2) (Panel B). High brain natriuretic
peptid level (582 ng/L) and elevated kappa light chains (29.5 mg/L) were observed. 99mTc-HMDP scintigraphy showed severe cardiac
uptake (Panel C). Valve calcium score was high (3925), suggesting severe AS (Panel D). However, associated CA was suspected because
of the echocardiographic and strain patterns, and was confirmed by endomyocardial biopsies.
This case illustrates that:
(1) CA can be associated with and considered as a potential explanation for LFLG AS with preserved EF.
(2) This diagnosis should be raised in AS patients presenting with suggestive echocardiographic findings.
(3) Multimodality imaging plays an important role in the assessment of patients with both AS and CA.
Supplementary data are available at European Heart Journal – Cardiovascular Imaging online.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2016. For permissions please email: journals.permissions@oup.com.
EACVI/EHRA Expert Consensus Document 383
Downloaded from https://academic.oup.com/ehjcimaging/article-abstract/17/4/355/2464865
by Belgrade University user
on 13 March 2018
